Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maze Therapeutics Inc (MAZE)

Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,927,166
  • Shares Outstanding, K 48,119
  • Annual Sales, $ 167,500 K
  • Annual Income, $ 52,230 K
  • EBIT $ -135 M
  • EBITDA $ -131 M
  • 60-Month Beta N/A
  • Price/Sales 11.65
  • Price/Cash Flow 264.87
  • Price/Book 5.14

Options Overview Details

View History
  • Implied Volatility 75.90% (+1.98%)
  • Historical Volatility 50.92%
  • IV Percentile 15%
  • IV Rank 6.19%
  • IV High 156.91% on 09/18/25
  • IV Low 70.56% on 12/22/25
  • Expected Move (DTE 16) 5.36 (13.28%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 382
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 300
  • Open Int (30-Day) 270
  • Expected Range 35.04 to 45.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.70
  • Number of Estimates 6
  • High Estimate -0.67
  • Low Estimate -0.75
  • Prior Year -18.32
  • Growth Rate Est. (year over year) +96.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.84 +9.99%
on 12/02/25
43.29 -6.40%
on 12/04/25
+2.77 (+7.34%)
since 11/28/25
3-Month
24.99 +62.14%
on 10/02/25
43.29 -6.40%
on 12/04/25
+14.59 (+56.27%)
since 09/30/25

Most Recent Stories

More News
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate...

MAZE : 40.54 (+1.22%)
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 40.54 (+1.22%)
Maze Therapeutics to Participate in Four Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 40.54 (+1.22%)
Maze Therapeutics Appoints Hervé Hoppenot as Chairman

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

MAZE : 40.54 (+1.22%)
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 40.54 (+1.22%)
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), I-MAB (IMAB – Research Report) and Cidara Therapeutics...

IMAB : 4.63 (-0.22%)
CDTX : 220.92 (+0.05%)
MAZE : 40.54 (+1.22%)
Analysts’ Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), Repligen (RGEN – Research Report) and Monopar Therapeutics...

MNPR : 64.55 (-0.80%)
RGEN : 164.37 (-1.33%)
MAZE : 40.54 (+1.22%)
Biotech Breakouts: 3 Stocks With Massive Upside Potential

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

VKTX : 34.94 (-1.08%)
MAZE : 40.54 (+1.22%)
IBRX : 1.9800 (-0.51%)
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 40.54 (+1.22%)
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid...

MAZE : 40.54 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases. Maze Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif....

See More

Key Turning Points

3rd Resistance Point 42.02
2nd Resistance Point 41.43
1st Resistance Point 40.74
Last Price 40.54
1st Support Level 39.47
2nd Support Level 38.88
3rd Support Level 38.19

See More

52-Week High 43.29
Last Price 40.54
Fibonacci 61.8% 29.32
Fibonacci 50% 25.00
Fibonacci 38.2% 20.68
52-Week Low 6.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar